	Application No.	Applicant(s)
	10/823,396	JONES ET AL.
Notice of Allowability	Examiner	Art Unit
	S. Devi, Ph.D.	1645
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication (GHTS. This application is subject t	plication. If not included n will be mailed in due course. THIS
1.   This communication is responsive to Applicants' amendments.	ent filed 9/19/07.	
2. The allowed claim(s) jet are 4 and 6-10, now renumbered a	as claims 1 and 2-6 respectively.	
Acknowledgment is made of a claim for foreign priority u     a) □ All b) □ Some* c) □ None of the:     1. □ Certified copies of the priority documents have	• (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
2.  Certified copies of the priority documents have		
3. Copies of the certified copies of the priority do		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
<ol> <li>A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give</li> </ol>		
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.	
(a) Including changes required by the Notice of Draftspers	son's Patent Drawing Review (PTO-	948) attached
1) Thereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment or in the C	Office action of
Identifying Indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	I.84(c)) should be written on the drawing the header according to 37 CFR 1.121(	ngs in the front (not the back) of d).
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT</li> </ol>		
Attachment(s)		
1. Notice of References Cited (PTO-892)	<ol><li>Notice of Informal P</li></ol>	atent Application
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	Paper No./Mail Da 7. ⊠ Examiner's Amendr	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	<ol><li>Examiner's Statement</li></ol>	ent of Reasons for Allowance
	9.  Other	9.

## ATTACHMENT TO NOTICE OF ALLOWABILITY

# Applicants' Amendment

 Acknowledgment is made of Applicants' election filed 09/19/07 in response to the non-final Office Action mailed 03/20/07.

#### Examiner's Amendment

2) An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants, an amendment may be filed as provided by 37 C.F.R 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. The authorization to prepare this Examiner's amendment was provided by Ms. Shilpa Patel in a telephonic interview on 04 December 2007.

This application has been amended as indicated below:

- (A) Claims 1-3, 5 and 11-69 have been canceled.
- (B) Claim 8 has been amended as indicated below:
- --Claim 8 (Currently amended). An expression vector comprising the nucleic acid molecule of claim 4. 6 or 7 operatively associated with an expression control sequence.--

## Status of Claims

3) Claims 1-5, 7 and 9 have been amended via the amendment filed 09/19/07.

Claims 1-3, 5 and 11-69 have been canceled via this Examiner's amendment.

Claim 8 has been amended via this Examiner's amendment.

Claims 1, 4 and 8-10 are pending and are under examination.

# Objection(s) Withdrawn

4) The objection to the specification made in paragraph 6 of the Office Action mailed 03/20/07 is withdrawn in light of Applicants' amendment to the specification.

# Rejection(s) Moot

5) The rejection of claims 1, 2, 5 and those dependent therefrom made in paragraph 10 of the Office Action mailed 03/20/07 under 35 U.S.C. § 112, first paragraph, as containing inadequate written description, is moot in light of the cancellation of claims 1, 2 and 5.

Application/Control No. 10/823,396 Art Unit: 1645 December 2007

- 6) The rejection of claims 1, 2 and 5 made in paragraph 11 of the Office Action mailed 03/20/07 under 35 U.S.C. § 112, first paragraph, as being non-enabling with regard to the scope, is moot in light of the cancellation of these claims.
- 7) The rejection of claim 2 made in paragraph 13(a) of the Office Action mailed 3/20/07under 35 U.S.C § 112, second paragraph, as being indefinite, is most in light of the cancellation of the claim.
- 8) The rejection of claim 1 made in paragraph 15 of the Office Action mailed 3/20/07 under 35 U.S.C § 102(b) as being anticipated by Bourgogne et al. (In: Abstracts of the 101st General Meeting of the American Society for Microbiology, Orlando, FL, USA, page 127, 20-24 May 2001 Applicants' IDS), is moot in light of the cancellation of the claim.

# Rejection(s) Withdrawn

- 9) The rejection of claim 9 (not 8 as mistyped inadvertently) made in paragraph 9 of the Office Action mailed 03/20/07 under 35 U.S.C. § 101 as being directed to non-statutory subject matter, is withdrawn in light of Applicants' amendment to claim 9.
- 10) The rejection of claims 8-10 made in paragraph 10 of the Office Action mailed 03/20/07 under 35 U.S.C. § 112, first paragraph, as containing inadequate written description, is withdrawn in light of the amendment made to claim 8.
- 11) The rejection of claims 8-10 made in paragraph 11 of the Office Action mailed 03/20/07 under 35 U.S.C. § 112, first paragraph, as being non-enabling with regard to the scope, is withdrawn in light of the amendment made to claim 8.
- 12) The rejection of claims 8-10 made in paragraph 13(a) of the Office Action mailed 3/20/07 under 35 U.S.C § 112, second paragraph, as being indefinite, is withdrawn in light of the amendment to claim 8.
- 13) The rejection of claims 8-10 made in paragraph 15 of the Office Action mailed 3/20/07 under 35 U.S.C § 102(b) as being anticipated by Bourgogne et al. (In: Abstracts of the 101st General Meeting of the American Society for Microbiology, Orlando, FL, USA, page 127, 20-24 May 2001 Applicants' IDS), is withdrawn in light of the amendment to claim 8.

## Remarks

- 14) Claims 4 and 6-10, now renumbered as claims 1 and 2-6 respectively, are allowed.
- 15) Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. The Fax number for submission of amendments, responses and/or papers is (571) 273-8300, which receives transmissions 24 hours a day and 7 days a week.
- 16) Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAG or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.Mov. Should you have questions on access to the Private PAA system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (in USA or CANADA) or 571-272-1000.
- 17) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Shanon Foley, can be reached on (571) 272-0898.

December, 2007

S. DEVI, PH.D.